BCL2 and Miyoshi myopathy: Importantly, MM patients with a (11:14) translocation [t (11:14)] express more Bcl-2 than Bcl-xL or Mcl-1 and respond well to venetoclax monotherapy (Kumar et al., 2017; Cleynen et al., 2018).